Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etaracizumab in Irinotecan-Refractory Advanced Colorectal Cancer
NCT00027729Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2001
- Primary completion
- Nov 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of etaracizumab in colorectal cancer (CRC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2001; status: completed.
02
Drugs
etaracizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00027729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027729.